51 results about "Immune cell infiltration" patented technology

The present application relates to a kind of pH / H2O2 dual-response drug-loaded hydrogel and its preparation method and application, by ε-polylysine derivative as antitumor active ingredient, with oxidized dextran through Schiff base reaction crosslinking rapid gelation. While using 2-formylphenyl boronic acid covalently package CD73 small molecule inhibitor APCP. ε-polylysine derivative has oncolytic activity, can induce ICD and promote the infiltration of immune cells in tumor cells. CD73 small molecule inhibitor APCP can block extracellular CD39-CD73-adenosine pathway, reduce the level of immunosuppressive metabolite adenosine in tumor tissue, so as to activate the infiltrated immune cells, restore its anti-tumor function. The hydrogel of ε-polylysine derivative and APCP co-delivery synergistically inhibits the effect of tumor growth, and its curative effect is greater than the treatment effect of single drug, and is superior to positive control drug oxaliplatin (OXA). The pH / H2O2 dual-response hydrogel is rapidly gelled, and has good biological safety under mild reaction conditions.

The invention discloses a myocardial ischemia reperfusion injury animal model construction method and application thereof in the technical field of model animal preparation. The method comprises the steps of hypertension and hyperlipidemia pretreatment, standardized ischemia-reperfusion operation, immune microenvironment regulation and control and model evaluation and verification. According to the invention, model construction is carried out on an integrated model operation table, so that a standardized ischemia-reperfusion process is realized, reproducibility of a myocardial injury degree and an immune cell infiltration rule of the model is realized, and suitability of the model and nano-drug research is enhanced; and a reliable tool is provided for research and development of targeted drugs such as immune cell membrane coated nanoparticles.

The invention discloses mizoribine for treating cerebral arterial thrombosis. It is found for the first time that mizoribine can reduce the cerebral apoplexy infarction area, inhibit immune cell infiltration of the brain, relieve inflammation of the cerebral parenchyma stroke part, improve damage to the nervous system of the stroke part and promote recovery of the damaged nerve function.

Described herein are gene panel compositions and methods of use thereof for spatial omic analysis in biological samples. The gene panels may be organized into distinct modules that target various aspects of immune response, tumor biology, and intercellular communication within the microenvironment. These methods involve spatial omic techniques, such as spatial transcriptomics, to localize gene expression across tissue sections, providing detailed insights into immune cell infiltration, immune checkpoint activation, and tumor-immune interactions. The disclosed compositions and methods are applicable for diagnostics, monitoring therapeutic responses, and guiding personalized treatment strategies. The modular design of the gene panels allows for customization based on specific research or clinical objectives.

The invention discloses a construction method of a spontaneous lupus adipositis animal model, which comprises the following steps: constructing keratinocytes with genotypes of PPAR [gamma] flox / flox- / -Krt5-CreERT < 2 + > / -Adipoq-Cre < + > / -and PPAR [gamma] flox / flox- / -Krt5-CreERT < 2 + > / -Adipoq-CreERT < 2 + > / -and fat cells into a conditional PPAR [gamma]-active receptor gamma gene knockout mouse, so as to construct the animal model with the spontaneous lupus adipositis animal model. Then knocking out PPAR gamma genes in keratinocytes and adipocytes by using a gene knockout activator, so that the mice spontaneously have the phenotypes of lupus septicaemia, including local skin unhairing, lipoatrophy, persistent skin lesion, proteinuria and serum autoantibodies; histological examination finds that lobular adipositis, glomerular volume increase, mesangial cell hyperplasia, inflammatory cell infiltration, glomerular IgG deposition and the like are mainly caused by dermal immune cell infiltration and subcutaneous fat layer lymphocyte infiltration, clinical symptoms of patients with lupus adipositis are simulated, and an important tool is provided for related research of lupus adipositis.

The invention provides a brain glioma immune microenvironment complexity assessment method and application, and the method comprises the following steps: obtaining m glioma samples, and carrying out transcriptome determination on each cell in each glioma sample to obtain transcriptional expression profile data of the cells; carrying out clustering analysis on transcriptional expression profile data of the single cells through K-means clustering, and preliminarily identifying lymphocytes and myeloid cells according to immune cell classical markers; carrying out clustering analysis on the identified transcription expression profile data of the lymphocytes and myeloid cells, and identifying n cell subgroups; calculating the enrichment score of the characteristic gene set of each cell subset in the glioma transcriptome sample, wherein the higher the score is, the higher the enrichment proportion of the cell subset in the sample is; and evaluating the complexity of immune cell enrichment in the glioma sample based on the enrichment score of the characteristic gene set. The immune cell infiltration complexity can be predicted, and the relationship between immune cell enrichment complexity and brain glioma prognosis can be identified.

The application discloses a double-drug self-enhanced layered double hydroxide nanosystem and application thereof. The iron-ruthenium layered double hydroxide in the nanosystem has double enzyme activity, can efficiently catalyze H2O2 to generate O2 and active oxygen in a tumor microenvironment, significantly relieves hypoxia while inducing oxidative stress, the MCT4 specific inhibitor VB124 in the system creates an acidic microenvironment by blocking lactic acid output, amplifies the catalytic efficiency of FeRu, and establishes a self-enhanced catalytic effect; and the co-loaded epigenetic regulator JQ1 down-regulates the expression of PD-L1 by inhibiting BET protein. The system amplifies the catalytic efficiency of FeRu, significantly induces ferroptosis, reverses the immunosuppressive microenvironment with the help of epigenetic regulation, induces the release of damage-associated molecular patterns, causes the infiltration of immune cells, and finally cooperatively triggers a strong anti-tumor immune response. The self-enhanced catalysis-epigenetic regulation synergistic strategy realized by the system provides an innovative solution for improving the effect of tumor immunotherapy.

The invention belongs to the technical field of biological medicines, and particularly relates to application of NLRC5 in targeted screening of medicines for improving immunotherapy of esophageal squamous carcinoma. NLRC5 expression is inhibited or regulated, and immunotherapy of esophageal squamous cell carcinoma is improved. The NLRC5 is highly methylated, and the expression of the NLRC5 in the ESCC is reduced. The NLRC5 is over-expressed, immune cell infiltration is promoted, meanwhile, immune escape is promoted by intensifying T cell depletion, immune checkpoint expression is up-regulated, and an immunosuppression state is created, so that anti-tumor immune response is potentially weakened. The invention discloses a polyhedral function of the NLRC5 in immune regulation and control from a single cell level, and particularly discloses close association of the NLRC5 with an immune checkpoint pathway and T cell depletion. A theoretical basis is provided for developing a therapy for targeting NLRC5, and a new way is possibly opened up for enhancing anti-tumor immune response. Researches show that NLRC5 is an important regulatory factor of immune response in ESCC, and plays a dual role in immune activation and immunosuppression.

The application provides an application of a hair follicle immune homeostasis regulation strategy in treating alopecia diseases. A group of pathological LAMP3 + CCR7 + IL4I1 + DC3 dendritic cell subpopulation. A DC3 dendritic cell subpopulation marker gene Il4i1 Drive conditionally knockout one of the CGRP receptor complexes Calcrl The constructed spontaneous alopecia areata animal model can well simulate the progressive and active hair loss of alopecia areata patients, form stable hair loss patches, and combine with pathological changes such as hair follicle immune cell infiltration, which indicates that the dendritic cell CGRP signal loss is an important inducement for mediating systemic alopecia areata. The application also discloses a pharmaceutical composition or kit for preparing a drug for relieving / treating hair loss, improving hair follicle homeostasis, or enhancing hair growth / black coloration (reducing white hair), which comprises: (a) a JAK kinase inhibitor, and (b) a neuropeptide CGRP or a receptor agonist thereof.

The invention discloses metal-based nanoparticles loaded with traditional Chinese medicine as well as a preparation method and application of the metal-based nanoparticles, and relates to the technical field of nano medical materials. The nano-particle is prepared by taking nickel iron zinc aluminum hydroxide as a multi-metal-based core carrier, carrying out PEG modification and cRGD peptide targeted coupling, and loading a traditional Chinese medicine active ingredient curcumin. The preparation is realized through a multi-step chemical coupling and loading process, and the multi-metal carrier can realize responsive structural disintegration and accurate controlled release of curcumin in a tumor weak acid environment. The nanoparticles have active targeting, multi-metal synergistic killing and immune regulation functions, can specifically recognize a triple negative breast cancer cell surface integrin alpha v beta 3 receptor, inhibit tumor cell proliferation, induce apoptosis, regulate BCR, IL-17 and other immune related signal channels, promote immune cell infiltration and remodel a tumor immune microenvironment. The metal-based nano-particles loaded with the traditional Chinese medicine are simple in preparation process, high in production efficiency and suitable for precise treatment of triple negative breast cancer.

The application relates to an endometriosis subtype identification method and system, relates to the fields of bioinformatics and medical diagnosis auxiliary technologies, and takes transcriptome expression data as input, constructs a standardized expression matrix, and adopts consistency clustering to perform subtype modeling to obtain a molecular subtype label; expression timing structure of a menstrual cycle phase is introduced to perform dynamic gene identification and discriminant power evaluation, and immune cell infiltration inference and path activity scoring are combined to analyze differences of the subtypes in an immune and inflammation network, then gene-pathway / gene-cell correlation is calculated to form multi-dimensional typing information with mechanism orientation. Based on the above results, an interpretable typing identification model is constructed, which provides a new technical means for accurate diagnosis and target identification of endometriosis.

The invention relates to an application of a soluble epoxide hydrolase inhibitor in the field of transplantation, the soluble epoxide hydrolase inhibitor is TPPU, and the soluble epoxide hydrolase inhibitor is applied in the fields of organ transplantation and tissue transplantation. The TPPU is used for relieving allogeneic mouse heart and skin transplantation immunological rejection, reducing immune cell infiltration in transplantation operation, and inhibiting CD4 + T cell proliferation, CXCR3 chemokine receptor positive and Th1 cell subset proportion. The TPPU inhibits proliferation of primary CD4 + T cells of normal mice and differentiation of Th1 cell subgroups. In organ transplantation and tissue transplantation, the invention provides a single soluble epoxide hydrolase inhibitor TPPU, which can relieve allogeneic mouse heart and skin transplantation immunological rejection, inhibit normal mouse primary CD4 + T cell proliferation and differentiation, and reduce toxic and side effects caused by the use of an immunosuppressant.

This invention belongs to the field of biomedical technology, specifically relating to an anti-tumor nanomaterial, its preparation method, and its application. The anti-tumor nanomaterial is formed by in-situ growth of calcium peroxide on the surface of black phosphorus nanosheets to create hierarchical black phosphorus-calcium peroxide nanosheets, followed by coating the surface of these composite nanosheets with hyaluronic acid. After entering tumor cells, the anti-tumor nanomaterial releases calcium ions and hydrogen peroxide, triggering an abnormal increase in calcium ions and oxidative stress within the cells, thereby causing mitochondrial dysfunction and inducing tumor cell death. Simultaneously, the released calcium ions combine with phosphate ions produced by the degradation of black phosphorus, forming calcium phosphate mineralization deposits within the tumor tissue, inducing tumor biocalcification. Changes in calcium signaling and the oxidative stress process can also promote the infiltration and activation of immune cells, thereby regulating the tumor immune microenvironment and achieving a synergistic effect of cell killing, biocalcification induction, and immune regulation within tumor tissue.

The invention belongs to the technical field of biological medicine and tumor immunotherapy, and discloses application of 3-oxo-valproic acid coenzyme A in preparation of a medicine for inhibiting lung adenocarcinoma. As a specific agonist of GIMAP1, the 3-oxo-valproic acid coenzyme A is used for activating the GIMAP1, enhancing inhibition of lung cancer cell progress and enhancing activation of a tumor immune microenvironment, so that the lung adenocarcinoma is inhibited, and the lung adenocarcinoma is inhibited. The invention has the following beneficial effects: 1, strong targeting property: 3-oxo-valproate coenzyme A is specifically combined with GIMAP1, so that a mediated immunomodulatory pathway is accurately activated, and wide influence on normal cells is avoided; 2, immune microenvironment remodeling: the anti-tumor immune cell infiltration is remarkably improved, the lung adenocarcinoma immunosuppression microenvironment is reversed, and the immunotherapy sensitivity is improved; 3, tumor progression is inhibited, lung cancer cell proliferation is effectively inhibited, and the tumor invasion ability is reduced; 4, the source is natural: as an intestinal microbial metabolite derivative, the safety is high, and the side effect is lower than that of a chemically synthesized medicine.

The invention discloses application of alpha-ketoglutaric acid in preparation of a medicine for preventing and / or treating antibody-mediated rejection reaction, and belongs to the technical field of biological medicine. According to the application, an acute antibody-mediated rejection reaction model of mouse skin pre-sensitization combined with kidney transplantation is constructed, and alpha-KG is applied for intervention. Results show that the alpha-KG can significantly improve renal functions (serum creatinine and urea nitrogen are reduced), prolong survival time of the transplanted kidney, relieve histological injury of the transplanted kidney (Banff score is reduced), inhibit deposition of complement C3d, reduce the level of a specific antibody (DSA) of a peripheral blood donor, down-regulate expression of kidney local inflammatory factors (Tnf, Il-6, Il-1beta and Nos2), regulate immune cell infiltration in the transplanted kidney, and improve the survival rate of the transplanted kidney. Comprising the steps of reducing transplantation kidney mononuclear / macrophage infiltration, reducing the proportion of transplantation kidney pro-inflammatory macrophages and increasing the proportion of repair macrophages. The application provides a new drug choice for treating the acute antibody-mediated rejection of the transplanted kidney, and has an important clinical application prospect.

The invention discloses application of GCH1 in diagnosis, treatment and prognosis of cervical cancer. Experiments prove that the GCH1 gene is closely related to the immune cell infiltration level and is remarkably related to a plurality of cervical cancer related genes; experiments prove that the GCH1 expression quantity in cervical cancer tissues is obviously higher than that in para-carcinoma tissues; meanwhile, the higher the expression of the GCH1 in the cancer tissue is, the better the prognosis effect of the patient is; the research finds that the GCH1 expression level has significant correlation with the cervical cancer FIGO clinical staging, so that the GCH1 expression level can be used for diagnosis and staging judgment of cervical cancer and prognosis evaluation. An active ingredient for inhibiting GCH1 expression is provided and can be used for treating cervical cancer; and the gene can also be used as a target spot for screening cervical cancer treatment drugs, so that the gene has a good practical application value.

This invention relates to the application of SMAD6 in the auxiliary diagnosis and prognostic assessment of TGCT. Based on TGCT samples, this invention identifies a novel TGCT prognostic biomarker (SMAD6) through differential analysis, Cox regression, and survival analysis. Subsequently, the expression level of SMAD6 in normal testicular tissue and TGCT was assessed by immunohistochemical staining. Finally, the relationship between SMAD6 and biological characteristics, mutant landscape, immune cell infiltration, and immunotherapy response was investigated. This invention clarifies that SMAD6 is a risk factor for poor prognosis in TGCT. Immunohistochemical results show that SMAD6 is highly expressed in TGCT tissues. GSEA indicates that SMAD6 is associated with the activation of tumor-related pathways and the inhibition of immune-related pathways. Furthermore, high SMAD6 expression is associated with lower CD8 levels. + T-cell infiltration is associated with low SMAD6 expression, and patients with low SMAD6 expression benefit more from immunotherapy.

The disclosure provides in one aspect compounds, and compositions comprising such compounds, that can be used to treat, ameliorate, and / or prevent cancer, especially colorectal cancer (CRC). In certain embodiments, the compounds of the disclosure inhibit HSP70. In other embodiments, the compounds of the disclosure promote or increase immune cell recruitment to a cancer. In yet other embodiments, the compounds of the disclosure promote and / or increase immune cell infiltration in a cancer.

The invention discloses a method for constructing a spontaneous systemic lupus erythematosus animal model, which comprises the following steps: knocking out EP300 (E1A Binding Protein P300) in keratinocytes to enable a mouse to spontaneously have systemic lupus erythematosus phenotypes, including local skin unhairing, persistent skin lesion, persistent proteinuria and serum autoantibodies; the systemic lupus erythematosus sample changes such as dermal immune cell infiltration and glomerular IgG deposition exist in histological examination, clinical symptoms of systemic lupus erythematosus are simulated, and an important tool is provided for related research of systemic lupus erythematosus.

The invention belongs to the technical field of medicines, and particularly relates to application of benzyl selenenitrile in preparation of a medicine for preventing and / or treating pancreatic cancer. The benzylselenenitrile can effectively inhibit in-vivo growth of pancreatic cancer by improving immune cell infiltration in a pancreatic cancer tumor microenvironment and a killing function of anti-tumor cells such as CD8 + T cells, so that the effect of preventing and / or treating the pancreatic cancer is achieved. Experimental results show that the structures of the liver, spleen, kidney and lung of the mouse subjected to BSC intraperitoneal injection treatment have no significant difference from those of a control mouse, and the proliferation capacity of bone marrow cells also has no significant difference, so that the BSC does not generate visceral organ and bone marrow toxicity.

The invention relates to the technical field of biomedicine, in particular to a sepsis marker screening method based on a peripheral blood mononuclear cell gene co-expression network, and the method comprises the following steps: obtaining a sample; carrying out batch RNA sequencing, differential expression analysis, weighted gene co-expression network analysis, cross analysis and protein interaction network analysis on the sample, and screening hub genes; performing function enrichment analysis and immune cell infiltration analysis on the hub gene, and screening out a core gene; and carrying out expression verification and clinical correlation analysis on the hub gene. Starting from the overall perspective of a gene network, the screened Hub gene has higher biological significance and reliability, through cross screening of WGCNA and differential expression analysis, the range of candidate genes is greatly narrowed, the screening efficiency and accuracy are improved, bioinformatics analysis, scRNA-seq cell localization and protein level experimental verification are integrated, and the screening method has the advantages that the screening efficiency is greatly improved, and the screening cost is reduced. A complete evidence chain is formed, and the credibility of the marker is ensured.

This invention belongs to the fields of disease diagnosis, prognosis, and molecular biology, specifically relating to the application of spermine synthase (SMS) in the diagnosis, prognosis, and prediction of response to immune checkpoint blockade (ICB) therapy in hepatocellular carcinoma (HCC). Research revealed that, compared to normal liver tissue, the expression of spermine synthase (SMS) is significantly upregulated in HCC; and high SMS expression is associated with poor clinicopathological features of prognosis. Furthermore, compared to the low SMS expression group, HCC patients in the high SMS expression group had significantly shorter overall survival, disease-specific survival, and progression-free survival, thus SMS overexpression predicts unfavorable outcomes. Simultaneously, SMS overexpression affects immune cell infiltration in HCC patients, leading to poor immune checkpoint blockade (ICB) responses and poor treatment efficacy for HCC. In conclusion, SMS can serve as a biomarker for the diagnosis and prediction of clinical outcomes in HCC, and also as a biomarker for predicting ICB treatment response.

This invention relates to polypeptides, specifically to a PD-1 and αvβ3 bifunctional polypeptide and its applications, the amino acid sequence of which is shown in SEQ ID NO.1. The PD-1 / αvβ3 bifunctional polypeptide can simultaneously inhibit the PD-1 / PD-L1 pathway and the αvβ3 pathway, not only inhibiting tumor growth and invasion and suppressing abnormal tumor angiogenesis, but also promoting immune cell infiltration into tumors by blocking the PD-1 pathway, inhibiting angiogenesis, and regulating PD-L1 expression, thereby modulating the tumor microenvironment and exerting a synergistic immune effect.

A recombinant vector, a lentivirus, a lung-exempt MSLN CAR-T cell, and an anti-tumor agent are provided. The recombinant vector includes a first nucleotide sequence, a second nucleotide sequence, and a third nucleotide sequence, the first nucleotide sequence encodes a mesothelin (MSLN)-binding domain, the second nucleotide sequence encodes a leukocyte immunoglobulin-like receptor (LIR-1), and the third nucleotide sequence specifically binds to a lung-highly-expressed molecule. The lentivirus is constructed using the recombinant vector. The lung-exempt MSLN CAR-T cell is constructed using the recombinant vector or the lentivirus. When the lung-exempt MSLN CAR-T cell enters lung tissue, the second nucleotide sequence binds to the lung-highly-expressed molecule through the third nucleotide sequence, inhibiting the killing function of CAR-T to avoid pulmonary toxicity; when the lung-exempt MSLN CAR-T cell infiltrates tumor tissue, the second nucleotide sequence is inactivated, activating CAR-T cells to kill tumor cells, offering the advantages of precise therapy and low side effects.

The invention provides an IgA nephropathy diagnosis model containing nine genes and an establishment method thereof, and relates to the field of IgA nephropathy biomedical diagnosis. The nine kinds of genes are CD160, CX3CR1, EPHA4, THBS1, HLA-DRA (human leukocyte antigen-DRA), FARP2, VASH1, TMSB4Y and RHBDD3 (recombined HBDD3). According to the method, activated signal channels are identified in an IgAN queue, then key genes in the channels are positioned, an IgAN diagnosis model is constructed by adopting a machine learning technology based on the key genes, and immune cell infiltration characteristics of the IgAN diagnosis model are further revealed by integrating data related to glomerular functions. Therefore, a foundation is laid for developing a potential treatment strategy.

According to the identification and application of the cell death and immunosuppression biomarkers of the sepsis patients in different life cycles, transcriptome data of the sepsis patients in different age groups and a normal control group are collected, differential expression gene analysis is performed by utilizing bioinformatics, immune cell infiltration is estimated in combination with a CIBERSORT algorithm, and the cell death and immunosuppression biomarkers of the sepsis patients in different life cycles are identified. And the relation between the DEGs and the specific immune cell subpopulation is discussed through correlation analysis. And taking an intersection with genes related to a programmed cell death mode, constructing a sepsis risk assessment model by using a machine learning algorithm, and quantifying the contribution of the genes to a sepsis prediction result through an SHAP algorithm. The constructed model is especially suitable for neonates, children and adult sepsis patients, can distinguish risk assessment of different age groups and identify key programmed cell death modes, provides new biomarkers and tools for early diagnosis, treatment and risk assessment of sepsis, and is beneficial to improvement of clinical treatment effect and patient prognosis.

The application provides a kind of marker for predicting the curative effect of lung cancer immunotherapy and the construction method of scoring system, and relates to the field of biotechnology.The inventors have found that the mRNA of CypB, the RNA transcribed by FAM83H-AS1 gene and LncRNA VPS9D1-AS1 are related to the prognosis of lung cancer, and the immune cell infiltration around lung cancer lesions is related to the treatment of lung cancer patients.Accordingly, the application takes the mRNA of CypB, the RNA transcribed by FAM83H-AS1 gene, LncRNA VPS9D1-AS1, panCK, CD3, CD4, CD8 and Foxp3 as markers, and provides a construction method of scoring system for predicting the curative effect of lung cancer immunotherapy.The scoring system constructed by the method can comprehensively evaluate the state of tumor and its microenvironment, accurately predict the progression risk and prognosis of lung cancer, and better guide clinical medication.

The application relates to the technical field of drug sensitivity prediction, and discloses a construction method of a platinum drug sensitivity prediction model and application thereof, which comprises the following steps: constructing a training set; according to the training set, a plurality of candidate models are trained through a plurality of machine learning algorithms respectively; and according to preset model indexes, the plurality of candidate models are screened to obtain at least two platinum drug sensitivity prediction models. Based on cancer type data of a target group, administered platinum drug type data, immune cell infiltration level data of tumor sample tissue and PTC data, a plurality of high-precision platinum drug sensitivity prediction models are trained by using a machine learning algorithm, and the platinum drug sensitivity prediction models can be used in combination with a hard voting method to realize accurate prediction of platinum drug sensitivity. The model has high prediction accuracy, is more targeted for the applicable population, has simple and clear prediction results, has a short use cycle and is low in cost.

Method and compositions for treating glioblastoma (GBM) and other cancers is disclosed, involving the combination of radiation therapy (RT), fatty acid synthase (FASN) inhibitors, and programmed cell death protein 1 (PD-1) inhibitors or programmed death ligand 1 (PD-L1) inhibitors. The disclosed approach addresses the technical problem of RT-induced immunosuppression and resistance in cancers by targeting RT-induced lipid metabolism, which promotes immune escape. FASN inhibitors block fatty acid synthesis, enhancing immune cell infiltration and restoring anti-tumor immunity. PD-1 / PD-L1 inhibitors further counteract immunosuppressive pathways to improve therapeutic efficacy. This combination therapy prolongs survival, induces immune memory, and is applicable to other cancers, including those exhibiting increased lipid content post-RT or chemotherapy, including melanoma, breast cancer, and lung cancer.

The invention belongs to the field of biological medicines, particularly discloses an application of NiMn-PB in preparation of an abdominal aortic aneurysm protection medicine, and discloses that NiMn-PB can obviously improve degradation of an aortic elastic fibrous layer caused by Ang II treatment and can relieve immune cell infiltration, inflammation release, ferroptosis and angiogenesis in aorta; after Ang II treatment, NiMn-PB is used for intervention, occurrence and development of the abdominal aortic aneurysm induced by Ang II can be relieved, and it is indicated that NiMn-PB can be used for preparing the medicine for relieving the abdominal aortic aneurysm.